Ahmedabad, India: Zydus Lifesciences Ltd. announced its unaudited consolidated financial results for the quarter and half year ended September 30th, 2026.

Key Financial Highlights

Q2 FY27 Highlights

  • Revenue from operations at Rs. 79,096 mn, up 29% over last year.
  • Research & Development (R&D) investments for the quarter stood at Rs. 6,573 mn (8.3% of revenues).
  • EBITDA for the quarter was Rs. 18,945 mn, down 6% y-o-y. EBITDA margin for the quarter stood at 24.0%.
  • Net Profit for the quarter was Rs. 9,255 mn, down 27% y-o-y.
  • Capex (organic) for the quarter was Rs. 4,655 mn.

H1 FY27 Highlights

  • Revenue from operations at Rs. 1,59,266 mn, up 25% over last year.
  • Research & Development (R&D) investments stood at Rs. 12,997 mn (8.2% of revenues).
  • EBITDA was Rs. 38,239 mn, down 7% y-o-y. EBITDA margin stood at 24.0%.
  • Net Profit was Rs. 18,859 mn, down 31% y-o-y.
  • Capex (organic) for the half year was Rs. 10,530 mn.
  • Net Debt to Equity ratio as on 30th September, 2026 was 0.19x while Net Debt to EBITDA stood at 0.62x at the end of September, 2026.

Consolidated Financial Results

Rs. mnQ2 Q2 % Gr.Q1 % Gr.
FY27FY26y-o-yFY27q-o-q
Revenue from Operations79,09661,23229.20%80,170-1.30%
EBITDA18,94520,158-6.00%19,294-1.80%
EBITDA margin (%)24.00%32.90% 24.10% 
PBT12,61716,942-25.50%13,691-7.80%
Net Profit9,25512,609-26.60%9,604-3.60%
Rs. mnH1H1% Gr.
FY27FY26y-o-y
Revenue from Operations1,59,2661,26,96925.40%
EBITDA38,23941,043-6.80%
EBITDA margin (%)24.00%32.30% 
PBT26,30836,492-27.90%

Our Q2 performance reflects strong, all-round momentum, spearheaded by our branded businesses in India, International Markets and Wellness. Notably, the share of branded sales in the US has risen to 16%, underscoring our steady shift towards a more differentiated, specialty-led portfolio. We look forward to the approval and launch of Saroglitazar in the US, our first indigenously discovered NCE, which marks a pivotal point in our evolution. Anchored in patient centricity and supported by robust quality systems, we remain committed to building long-term growth levers and enhancing returns for all our stakeholders.

Dr. Sharvil Patel, Managing Director – Zydus Lifesciences Limited